Shilajit Research Library

We do not treat a 12-rat study the same as a double-blind 60-person randomised trial. Every study in this library carries an explicit evidence tier.

Tier A is a human randomised controlled trial, Tier B is a systematic review or non-randomised human study. Tier C is animal or in vitro mechanistic work, and Tier D is foundational chemistry or method.

Where a trial tested purified shilajit (PrimaVie or equivalent Eurofins-verified material) we flag it. Results from unpurified or undefined material are not interchangeable with results from purified resin.

The library spans 1991 to 2026, covers seven benefit categories, and is updated whenever a new peer-reviewed shilajit paper is indexed in PubMed. Flag a missing study at care@theyetilife.com.

Featured Studies — 4 Tier A Human RCTs

Of the 17 studies in this library, four are Tier A randomised controlled trials in humans. These are the papers we rely on for every clinical statement on this site.

Each was conducted with purified shilajit material (PrimaVie or equivalent Eurofins-verified resin) comparable to the batches we ship.

Evidence Tiers — How to Read This Library

Higher tier means stronger evidence for humans. We never cite an animal study to claim a human effect.

Every clinical statement on theyetilife.com is backed by a Tier A or Tier B paper from this library. Or it carries an explicit caveat naming the evidence gap.

1. Tier A · Human RCTRandomised, controlled trial in humans. The strongest evidence available for a supplement claim. Four of the studies in this library are Tier A. We rely on these for clinical statements about testosterone, muscle strength, collagen, and bone density.
2. Tier B · Systematic review or non-randomised human studyA comprehensive review of the human evidence base, a market survey of commercial products, or a contamination analysis. Strong but indirect — the evidence is about the field, not a single controlled experiment.
3. Tier C · Animal or in vitro mechanistic studyRodent behavioural tests, cell-culture biochemistry, mitochondrial assays, and toxicology in rats. Useful for proposing a mechanism, not for claiming a human outcome.
4. Tier D · Foundational chemistry or authoritative reviewPapers that define what shilajit is — its chemical constituents, its authenticity biomarkers, its pharmacopeial specifications. The reference texts every other shilajit paper cites.

Testosterone & Male Fertility

Three randomised controlled trials in healthy and subfertile men, plus a supporting rodent study. Together these set up the most rigorous human evidence shilajit has for any endpoint.

1. Pandit et al. (2016) — Purified shilajit raises testosterone in healthy men · Tier AAndrologia. 90-day randomised, double-blind, placebo-controlled trial in 75 men aged 45–55 receiving 250 mg purified shilajit (PrimaVie) twice daily. Significant increase in total testosterone (+20.4% vs placebo), free testosterone, and DHEAS. No safety signals at 500 mg/day. The cleanest causal evidence that purified shilajit raises testosterone in middle-aged men — PrimaVie is Eurofins-standard, comparable to our batches. PubMed PMID 26395129.
2. Biswas et al. (2010) — Processed shilajit in men with low sperm counts · Tier BAndrologia. 90-day study without a placebo group. 35 men with sperm counts below 20 million/ml took 100 mg processed shilajit twice daily; 28 completed. Versus their own baseline: total sperm count +61.4%, motility +12.4–17.4%, normal sperm +18.9%, serum testosterone +23.5% and FSH +9.4%; liver and kidney tests unchanged. Consistent with Pandit (2016), but weaker evidence because there was no control group. PubMed PMID 20078516.
3. Keller et al. (2019) — Shilajit and strength retention after fatiguing exercise · Tier AJournal of the International Society of Sports Nutrition. 8-week RCT in 63 recreationally active men: 250 mg/day, 500 mg/day or placebo. In the stronger half of participants, the 500 mg group lost less strength after a fatiguing exercise test (8.9% versus 16–17%) and had lower serum hydroxyproline, a collagen-breakdown marker. 250 mg did not differ from placebo. PubMed PMID 30728074.
4. Park et al. (2006) — Spermatogenic and ovogenic effects in rats · Tier CJournal of Ethnopharmacology. Six-week rat study. Treated males had significantly higher sperm counts in the testes and epididymides than controls, with no change in organ weights; in females, ovulation was induced in 7 of 9 treated rats versus 3 of 9 controls. Animal model only — not a substitute for human trials. PubMed PMID 16698205.

Muscle Strength & Physical Performance

Human RCT coverage for dermal collagen biosynthesis, plus preclinical support for the fatigue-reduction claims users describe.

1. Neltner et al. (2024) — Shilajit and a marker of type 1 collagen synthesis · Tier AJournal of Dietary Supplements. 8-week RCT in 35 recreationally trained men: 500 mg/day, 1,000 mg/day or placebo. Both shilajit doses significantly increased serum pro-c1α1, a blood marker of type 1 collagen synthesis. It measured a blood marker, not skin. PubMed PMID 36546868.

Cognitive Function & Neuroprotection

Two published mechanistic papers on fulvic acid's interaction with Alzheimer-relevant tau protein aggregation. Plus a broader Andean rock-exudate review.

We flag the clinical gap explicitly — no human Alzheimer or cognitive-decline RCT has been run for shilajit.

1. Cornejo et al. (2011) — Fulvic acid inhibits tau fibril aggregation · Tier CJournal of Alzheimer's Disease. In vitro biochemistry using the fulvic acid fraction of shilajit. Fulvic acid prevented the aggregation of tau protein into paired helical filaments and promoted disassembly of pre-formed filaments. A plausible molecular mechanism for shilajit's cognitive claims — not yet clinical evidence. PubMed PMID 21785188.
2. Carrasco-Gallardo et al. (2012) — Andean shilajit as Alzheimer's candidate · Tier DInternational Journal of Alzheimer's Disease. Review of chemistry and CNS literature. Reviews the biochemical rationale for fulvic acid as an anti-aggregation agent against tau. Proposes shilajit as a candidate for clinical neuroprotection trials. The most-cited cognitive review in the shilajit literature — supports the mechanism but explicitly flags the absence of clinical trials. PubMed PMID 22482077.

Bone Health & Postmenopausal Women

One long-duration randomised trial in postmenopausal women. The longest human shilajit RCT in the literature.

1. Pingali & Nutalapati (2022) — Bone mineral density in postmenopausal women · Tier APhytomedicine. 48-week RCT in 60 postmenopausal women aged 45–65 with osteopenia: placebo, 250 mg or 500 mg shilajit extract daily. Bone density at the lumbar spine and femoral neck fell on placebo, but the loss was dose-dependently reduced with shilajit (p<0.001), with favourable changes in bone-turnover, oxidative-stress and inflammation markers. PubMed PMID 35933897.

Chemistry, Authenticity & Biomarkers

These papers define what shilajit is — its chemical constituents, how to authenticate it, and how it varies by geographic origin.

1. Ghosal et al. (1976) — Shilajit I: chemical constituents · Tier DJournal of Pharmaceutical Sciences. One of the first chemical analyses of shilajit, describing its main organic and mineral constituents. Later research identified dibenzo-alpha-pyrones and fulvic acid as its key active fractions (see Stohs 2014). PubMed PMID 932958.
2. Agarwal et al. (2007) — Shilajit: a review · Tier DPhytotherapy Research. Review describing shilajit as a complex mixture of humic substances and plant and microbial metabolites, its traditional use as a rejuvenator and adaptogen, and which of its attributed properties modern research has checked. PubMed PMID 17295385.
3. Scientific Reports (2026) — Plant-derived phenolic acids in shilajit across five regions · Tier DScientific Reports. HPLC-MS/MS quantification of nine phenolic acids in eleven shilajit samples from Iran, India, Nepal, Russia and Kyrgyzstan. Gallic acid was the most abundant, reaching 2,839 µg/g in an Iranian sample, and most samples carried more hydroxybenzoic than hydroxycinnamic acids. The pronounced geographic variation is read as evidence of a plant-derived origin, and supports the view that provenance is a measurable chemical difference rather than a marketing claim. The study measured phenolic acids only — it did not assess fulvic acid or dibenzo-α-pyrones. Nature Scientific Reports, 2026.

Safety, Toxicology & Adulteration

The safety profile of purified shilajit is a work of purification, not of shilajit itself. Every batch must be independently lab-tested for heavy metals — a point these four papers repeatedly make.

1. Stohs (2014) — Safety and efficacy of shilajit · Tier BPhytotherapy Research. Review of animal and human studies. Concludes that shilajit's safety is well documented, reports antioxidant, anti-inflammatory, adaptogenic and immunomodulatory activity, and names dibenzo-alpha-pyrones and fulvic acid as the key active constituents. Calls for more well-controlled human studies using standardised products. PubMed PMID 23733436.
2. Wilson et al. (2011) — Review on shilajit used in traditional Indian medicine · Tier DJournal of Ethnopharmacology. Review of shilajit in Ayurveda and Siddha medicine: origin, varieties, physical properties, chemical constituents and biological activities, focusing on antioxidant and immunomodulatory activity. Lists 20 classical formulations and 24 proprietary products that contain it. PubMed PMID 21530631.
3. Quantifying of thallium in shilajit and its supplements (2025) · Tier BBMC Chemistry. Thallium measured at up to 0.226 µg/g in natural shilajit and up to 0.5 µg/g in supplements, with some supplements higher than the crude material. Thallium is not covered by standard Ayurvedic pharmacopeia heavy-metal panels. Standard four-metal testing is no longer enough — we added thallium to our Eurofins panel on batches from 2025 onward. BMC Chemistry, 2025 · PubMed PMID 39827344.
4. Velmurugan et al. (2012) — 91-day safety study of shilajit in rats · Tier CAsian Pacific Journal of Tropical Biomedicine. Rats received 500, 2,500 or 5,000 mg/kg daily for 91 days. Organ weights were normal and tissues looked normal apart from negligible liver and intestinal changes at the highest dose, where liver iron was also raised. Supports Stohs (2014) on safety at far lower human doses. Animal model only. PubMed PMID 23569899.

The contamination and authenticity criteria in this section are applied to commercial products in our brand-by-brand review of Indian shilajit lab data.

Stress, Anxiolytic & Adaptogenic Effects

Animal behavioural data and mitochondrial mechanism — but no human RCT for anxiety or stress especially. We do not claim anxiolytic effects from shilajit on this site.

1. Jaiswal & Bhattacharya (1992) — Anxiolytic activity of processed shilajit in rodent models · Tier CPhytotherapy Research. Elevated plus-maze and forced-swim testing in rats. Shilajit-treated rats showed reduced anxiety-like behaviour in standard behavioural paradigms, with effect sizes comparable to low-dose diazepam in some endpoints. The original citation for shilajit's anxiolytic claim — animal-only, do not extrapolate to human anxiety treatment without a clinician. Phytotherapy Research, 1992.
2. Surapaneni et al. (2012) — Shilajit in a rat model of chronic fatigue · Tier CJournal of Ethnopharmacology. Rats were made to swim for 15 minutes a day for 21 days to model chronic fatigue. Processed shilajit standardised to dibenzo-alpha-pyrones, DBP-chromoproteins and fulvic acids (25–100 mg/kg) reversed fatigue-related behaviour; the authors report effects on the stress-hormone (HPA) axis and mitochondrial energy production in the brain. Preclinical only. PubMed PMID 22771318.

5 New Studies Added — May 2026 Audit

Our monthly PubMed audit surfaced five new shilajit papers published in 2026. As with every entry, we summarise what each study does and — just as important — does not show, and we tag the evidence tier. The honest pattern for 2026 so far: the literature is broadening (a human resin pilot, animal and cell work, analytical chemistry, and a preclinical review) but it is not yet delivering large, definitive human trials. Read these as signposts that justify further research, not as proof of new clinical benefits.

1. Shilajit resin and physical performance — 28-day human pilot

[Tier B · Human pilot] This is the most directly consumer-relevant 2026 paper because it tested the traditional resin rather than a standardised extract. In a single-arm, open-label pilot, 25 healthy, moderately active men aged 21–55 took 500 mg/day of shilajit resin for 28 days. The authors reported within-group improvements in one-rep-max leg-press strength (+12.9%), muscle endurance (+12.3%), grip strength and VO₂max, alongside reductions in fatigue scores (−32%), perceived exertion and C-reactive protein (−25%), plus a small rise in lean mass. No serious adverse events were recorded. The caveats are substantial and the authors state them plainly: there was no placebo group, so expectation and training effects cannot be excluded; the sample was small and male-only; and the study was conducted by a supplement company's research team. It is encouraging early evidence that resin merits proper trials, not proof of a 13% strength gain. Yadav 2026, Cureus (PMID 41613504)

2. Composition across five regions — what is really in shilajit

[Tier C · Analytical] Using HPLC-MS/MS, researchers quantified nine plant-derived phenolic acids (including gallic, vanillic, syringic, caffeic and ferulic acids) across 11 shilajit samples from Iran, India, Nepal, Russia and Kyrgyzstan. The headline finding is the pronounced variation by geographic origin — gallic acid, the most abundant compound, ranged widely between regions. Beyond confirming a plant-derived contribution to shilajit's antioxidant profile, the practical message for buyers is blunt: "shilajit" is not a single standardised substance, and a product's source plus a current certificate of analysis tell you far more than the marketing word "Himalayan." This is exactly why we publish per-batch composition data rather than relying on origin claims. Kamgar 2026, Scientific Reports (PMID 41699045)

3. Liver protection — preclinical (cell and mouse)

[Tier D · Animal / Mechanism] In HepG2 liver cells and in mice, shilajit extract (known in Tibetan/Chinese medicine as ZhaXun) reduced acetaminophen-induced acute liver injury. Pretreatment lowered plasma ALT and AST markedly (≈75% and ≈70%), improved oxidative-stress markers (SOD, MDA, CAT, GSH), reduced inflammatory cytokines (TNF-α, IL-6, IL-1β) and limited hepatocyte apoptosis, apparently via PI3K/AKT and TLR4/NF-κB signalling. This is mechanistically coherent and consistent with shilajit's antioxidant reputation — but it is preclinical evidence at gram-per-kilogram animal doses. It does not show that swallowing resin protects human livers or offsets paracetamol toxicity, and no one should treat it as license to do so. He 2026, Journal of Ethnopharmacology (PMID 40957543)

4. Constituent separation and osteoporosis docking

[Tier D · Analytical + in-silico] This study separated shilajit's chemical constituents using inner-recycling counter-current chromatography and then ran molecular-docking simulations to explore how those constituents might interact with osteoporosis-related targets. Its value is twofold: a cleaner analytical method for isolating shilajit compounds, and computational hypotheses about bone-related activity. Both are useful for researchers, but molecular docking is a screening tool, not clinical proof — it predicts binding, not real-world effect. Treat any "shilajit for bone" implication here as a hypothesis awaiting cell, animal and human testing. Aziz 2026, Journal of Pharmaceutical and Biomedical Analysis (PMID 41297104)

5. Shilajit in cancer — preclinical systematic review

[Tier C · Systematic review of preclinical data] This systematic review collated laboratory and animal studies of shilajit in cancer models. We catalogue it for completeness and transparency, with the most important caveat in this library: it summarises preclinical research only. It is not evidence that shilajit prevents, treats or cures cancer in humans, and nothing in it should inform any treatment decision. If you or someone you know is facing cancer, the only appropriate next step is a qualified oncologist — not a supplement. Das 2026, Cureus (PMID 41640940)

With these five additions, the library now catalogues 17 peer-reviewed studies. Note what the 2026 cohort does and does not change: it deepens the mechanistic and compositional picture and adds one small human resin pilot, but the strongest human evidence still rests on a limited set of earlier randomised trials. Our position is unchanged — shilajit is a promising, mineral-rich adjunct backed by growing but mostly early-stage science, and product quality (verified fulvic acid, third-party heavy-metal testing) matters as much as the biology.

How We Apply This Literature

Three rules govern how Yeti Life cites research on every page of this site.

1. Tier before headlineWe never cite an animal study to claim a human effect. Every clinical claim on the site is backed by a Tier A or Tier B paper from this library — or it carries an explicit caveat naming the evidence gap.
2. Purified material onlyStudies that used unpurified or undefined shilajit are noted but not used to support product claims. Our batches are tested to the same pharmacopeial standard as the PrimaVie material used in the Pandit, Keller, and Das RCTs.
3. Absence of evidence is absence of claimNo published human RCT for anxiety, diabetes, thyroid, PCOS, or weight loss means we do not make those outcome claims. We cite the mechanistic papers and flag the clinical gap rather than silently inherit the hype.

This library supports the clinical and biochemical claims across our three pillar pages — Shilajit: The Complete Evidence-Based Guide, Our Sourcing, and Lab Results. Every claim on those pages traces back to one or more of the 17 studies catalogued here.

Frequently Asked Questions

How to Cite This Library

When you reference a study you found here — or the library itself as a source — use one of the formats below. Link to a specific section using its anchor (e.g.

#testosterone, #safety, #chemistry).

Permanent URL: The Yeti Life Shilajit Research Library (theyetilife.com/pages/research)

@misc{yetilife2026shilajit,
 author = {{Yeti Life Research Team}},
 title = {Shilajit Research Library: 17 Peer-Reviewed Studies (1991--2026)},
 year = {2026},
 url = {https://theyetilife.com/pages/research},
 note = {Accessed: [Date]}
}

License & Reuse

CC BY 4.0The curation, evidence tiers, and editorial summaries on this page are licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You may quote, translate, share, and republish any section with credit to “Yeti Life Research Team” and a link back to this page.

The underlying peer-reviewed studies are under their original publisher licenses — follow the PubMed or journal link on each entry for those terms.

For Journalists, Writers & Researchers

Writing about shilajit? Our research team is available to confirm a citation, provide background on an emerging study.

Or comment on contamination/quality-control findings. Email care@theyetilife.com — we reply within 48 hours and never ghost a journalist.

Quotable data points, attribution needed:

Update Log

For our full research method and correction policy, read our Editorial Policy.